Cellgenic

What Cellgenic does

Cellgenic is a provider-only regenerative medicine platform that supplies verified physicians, clinic owners, and researchers with cells, exosomes, peptides, and hormones manufactured in its own cGMP-certified, ISO Class 7 cleanroom laboratory in Cancun, Mexico. The portfolio is organized around four pillars — Cells (MSC variants, MUSE cells, bone marrow kits, collagenase), Exosomes (flagship ExoElite 70 at 70B, Flow 15B/50B, lyophilized), Peptides (BPC-157, Tirzepatide, Ipamorelin, and 25+ compounds available as vials, pens, and nasal sprays), and Hormones (bioidenticals in development for 2026) — with pre-configured clinical protocol bundles mapping to 15+ use cases such as acute musculoskeletal injury, chronic inflammatory pain, hormonal/GH axis re-establishment, and GLP-1 metabolic protocols.

The core technology is vertically integrated biologics manufacturing under a five-stage chain of custody: donor screening with COA on inputs, cell expansion and vesicle isolation, USP <71>/<85> sterility and endotoxin QC, lyophilized or cryopreserved packaging with batch-stamped COA in every box, and GDP-compliant cold-chain shipping with temperature loggers and signature-on-receipt. Every batch ships with full COA documentation archived in the provider portal, and the company holds ISO 20387 biobanking accreditation. The platform serves 1,400+ verified providers across seven markets (Mexico, Argentina, Colombia, Peru, USA, Panama, Costa Rica) and operates an Authorized/Exclusive Distributor Program spanning 30+ countries with tiered investment budgets of $100K–$5M USD.

Cellgenic is a wholly-owned subsidiary of Regenerative Medical Technologies Group, Inc. (RMTG), itself under Global Stem Cells Group Inc., with commercial headquarters in Miami, FL. Revenue is generated through wholesale biologics product sales, protocol bundle sales, distributor licensing/partnerships, and paid workshop and webinar training. Q1 2026 product supplies revenue reached $1,267,076, representing 102% YoY growth, with RMTG consolidated Q1 2026 revenue of $2,639,353 (+93% YoY). Pricing is gated behind provider verification and not publicly disclosed.

Name

Cellgenic

Legal name

CellGenic Laboratories

Website

https://cellgenic.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Cellgenic is a provider-only regenerative medicine platform supplying verified physicians and clinics with cells, exosomes, peptides, and hormones manufactured in its own cGMP-certified laboratory in Cancun, Mexico, and distributed across 30+ countries.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

akta.pro secondary industry

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

• Regenerative medicine biologics
• Cell therapy products
• Exosome manufacturing
• Peptide therapy supply
• GMP biologics production

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Biologics Product Sales: Cellgenic manufactures and sells research-grade cells, exosomes, peptides, and equipment to verified physicians, clinics, and researchers. Products include MSC lines (10M/20M/30M/50M/100M cells per vial), exosome preparations (ExoElite 70 at 70B, Flow 15B, Flow 50B, Lyophilized at 5B), peptide vials and pens (BPC-157, Tirzepatide, Ipamorelin, GHK-Cu, CJC-1295, DSIP, Epitalon, AOD-9604, MOTS-C, and 30+ other peptides), bone marrow kits, collagenase, PRP kits, and laboratory equipment. Minimum order quantities apply (e.g., 5 vials for MSC 50M). Cold-chain shipping (overnight, $250 USD for cold chain products) adds to product revenue.
2. Protocol Bundle Sales: Cellgenic packages multiple products into clinical-ready protocol bundles (Acute Musculoskeletal Injury, Chronic Inflammatory Pain, Infection/Wound Recovery, Hormonal/GH Axis, Sexual Function Optimization, Cognitive & Resilience, Immune & Inflammation, GLP-1 Metabolic protocols) sold as curated sets to providers.
3. Distributor/Partner Licensing: Cellgenic generates revenue through its Authorized and Exclusive Distributor Program, where distributors pay wholesale pricing and potentially exclusivity fees to gain rights to the full product portfolio in assigned territories. The program includes training, co-branded marketing materials, and priority restocking. Investment budgets of $100K–$5M USD are requested.
4. Workshop & Training Revenue: Cellgenic conducts in-person workshops and webinars in key markets. Paid workshop tiers (CORE from £55, PLUS from £245, PEAK from £725) offer escalating access to sessions covering the full portfolio, application protocols, live Q&A, networking, bookable workshops, food/beverages, and goodie bags.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Cellgenic manufactures and supplies research-grade cells, exosomes, peptides, and laboratory equipment to verified physicians, clinics, and researchers through a gated provider-only platform. Production takes place at a cGMP-certified, ISO Class 7 cleanroom facility in Cancún, Mexico, with xeno-free processes and ISO 20387 biobanking alignment. The company also distributes clinical protocol bundles and runs a global Authorized Distributor Program operating in 30+ countries.

Product overview

Cellgenic is a provider-only regenerative medicine platform supplying verified physicians, clinics, and researchers with research-grade biologics manufactured in its own cGMP-certified laboratory in Cancún, Mexico. The portfolio is organized around four pillars: Cells (MSC variants, MUSE Cells, Bone Marrow Kit, Collagenase), Exosomes (ExoElite 70 flagship, Flow 15B/50B, Lyophilized Exosomes), Peptides (BPC-157, TB-500, GHK-CU, Ipamorelin, CJC-1295, Tirzepatide, and 25+ other peptide compounds available in vials, pens, and nasal sprays), and Hormones (bioidentical hormones in development for 2026). Products are supported by protocol bundles for clinical use cases, laboratory equipment, distribution partnerships, training programs, and a peptide calculator tool. Every batch is COA-traced with sterility, endotoxin, mycoplasma, identity, and potency testing. The company operates an Authorized Distributor Program spanning 30+ countries and serves seven markets: Mexico, Argentina, Colombia, Peru, USA, Panama, and Costa Rica.

Differentiator

Problem solved

Functional benefit

Brands

• ExoElite 70: CellGenic's flagship exosome preparation — a 70 Billion exosome formulation in 5 mL, developed for professional regenerative environments requiring standardized production and batch consistency.
• Global Stem Cells Group

Products and services

• ExoElite 70

Quantifiable outcome

• Q1 2026 product supplies revenue of $1,267,076 — a 102% year-over-year increase (Q1 2025 to Q1 2026)
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core.

• ISSCA (International Society for Stem Cell Application)coreStrategic or Co-development Partner · 1 September 2025Cellgenic's Cancún manufacturing facility had its soft opening at the ISSCA Global Regenerative Medicine Summit in September 2025, aligning with ISSCA-accredited educational programs. ISSCA's physician training division (ISSCA) saw revenue surge 433% YoY in Q1 2026 to $772,005, indicating a deeply integrated relationship between Cellgenic's product supplies and ISSCA's training network.
• COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)coreOthersCellgenic's Cancún xeno-free biologics manufacturing facility operates under COFEPRIS-guided frameworks, producing and distributing six biologic product lines to international markets under Mexican regulatory oversight. COFEPRIS guidance enables the facility's compliant operation and international distribution.
• Global Stem Cells Group Inc.coreOthersGlobal Stem Cells Group Inc. is the parent company of Cellgenic. Cellgenic's advanced biologics manufacturing facility was announced through Global Stem Cells Group's subsidiary structure. The parent company provides the corporate umbrella, distribution infrastructure, and commercial headquarters in Miami, FL (9100 S Dadeland Boulevard, Suite 1500).

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Kimera Labs: Miami-based exosome and stem cell manufacturer serving regenerative medicine clinics with provider-gated distribution — directly comparable product mix, geographic focus, and B2B sales motion to Cellgenic.
• Pluristem Therapeutics: Publicly listed developer of allogeneic placenta-derived cell therapies with proprietary 3D bioreactor manufacturing — comparable as a competing allogeneic cell therapy manufacturer targeting regenerative indications.
• Direct Biologics: Develops and manufactures exosome-based therapeutics (ExoFlo) for regenerative medicine applications, with a vertically integrated laboratory and distribution platform serving physicians.
• Hope Biosciences: Autologous and allogeneic stem cell therapy developer/manufacturer with proprietary cGMP manufacturing supplying regenerative medicine protocols to physicians and clinics.
• Stemedica Cell Technologies: cGMP manufacturer of allogeneic adult stem cell products for clinical and research use, supplying regenerative medicine providers with characterized cell lines — directly comparable in production and target customer.
• Personalized Stem Cells: FDA-registered manufacturer of autologous stem cell products for clinical use, operating a cGMP-compliant production facility serving regenerative medicine providers.

Broad incumbents

• Lonza Cell & Gene Technologies: Global CDMO with established cell therapy manufacturing services and commercial fill-finish capabilities — overlapping capabilities with Cellgenic's cGMP biologics manufacturing, but at vastly larger scale and across a broader portfolio.
• WuXi Advanced Therapies: Large cell-and-gene therapy CDMO with cGMP manufacturing capacity for regenerative medicine clients — broad incumbent in the same end-customer category as Cellgenic's manufacturing platform.

Emerging players

• Stemmatters: Regenerative medicine CDMO providing cell and tissue manufacturing services to clinics and research institutions — a partial-overlap peer operating at smaller scale in adjacent geographies.
• Regen Bio: Emerging exosome manufacturer focused on regenerative aesthetics and longevity markets — partial overlap with Cellgenic's exosome pillar and provider-clinic distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Instagraminstagram.com/cellgenic
• Facebookfacebook.com/cellgenic
• LinkedInlinkedin.com/company/cellgenic

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellgenic